A pharmaceutical company that develops drugs that block Cav3.2 for the prevention & treatment of neuropathic pain.
Xdynia is a drug development company that possesses drugs targeting Cav3.2 for the prevention & treatment of neuropathic pain. Chronic pain affects 76 million Americans with 60% reporting no relief from available therapies. Whether caused by diabetes, shingles, fibromyalgia, “slipped disk”, chemotherapy or cancer, the Cav3.2 is a common pathway. A potential $25 B market, Xdynia is poised to introduce a better class of drugs to treat pain.